Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Teneligliptin and Empagliflozin in Healthy Adults
NCT04431141Phase 1Completed
- Sponsor
- Handok
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of teneligliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Handok. Primary endpoints: Maximum Plasma Concentration at Steady State at 72 hours and Area Under the Curve Over the Dosing Interval at Steady State at 72 hours. Started Sep 2020; status: completed.
02
Drugs
teneligliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04431141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04431141.